Repositioning Candidate Details

Candidate ID: R0720
Source ID: DB05159
Source Type: investigational
Compound Type: small molecule
Compound Name: CCX915
Synonyms: --
Molecular Formula: --
SMILES: --
DrugBank Description: CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.
CAS Number: --
Molecular Weight:
DrugBank Indication: Investigated for use/treatment in multiple sclerosis and neurologic disorders.
DrugBank Pharmacology: --
DrugBank MoA: Mechanism of action indicates that CCX915 selectively inhibits CCR2-mediated migration of inflammatory white blood cells, but do not inhibit migration mediated by other chemokine receptors, even when administered at high concentrations. Based on the high degree of target specificity observed, CCX915 has the potential to avoid the undesirable side effects of traditional immunosuppressive therapies used in MS and other autoimmune disease indications.
Targets: C-C chemokine receptor type 2
Inclusion Criteria: Therapeutic strategy associated